Skip to main content
Top

08-06-2024 | Systematic Review

Efficacy and Safety of Alprostadil in Microcirculatory Disturbances During Emergency PCI: A Meta-Analysis of Randomized Controlled Trials

Authors: Yue Chen, Mengdi Wang, Yali Yang, Min Zeng

Published in: American Journal of Cardiovascular Drugs

Login to get access

Abstract

Objective

The clinical advantage of alprostadil [prostaglandin E1 (PGE1)] in the treatment of microcirculatory disturbances (defined as no-reflow or slow-flow) in acute percutaneous coronary intervention (PCI) is still disputed. The purpose of our study was to review the efficacy of PGE1 supplements in patients with acute myocardial infarction (AMI) who had urgent PCI.

Design

This study was a meta-analysis of randomized controlled trials.

Data Sources

PubMed, Embase, the Cochrane Library, Ovid, ProQuest, Scopus, the Chinese BioMedical Literature Database, China National Knowledge Internet, the China Science and Technology Journal Database, and the Wanfang Data Knowledge Service Platform were used as sources.

Eligibility Criteria for Selecting Studies

We included randomized controlled trials including PGE1 for the treatment of intraoperative microcirculatory disorders and major cardiovascular adverse events in emergency PCI in people with AMI. Independent data extraction was conducted, and study quality was assessed. The meta-analysis was carried out by using random effects models to calculate the risk ratio (RR) of microcirculatory disorders between groups receiving PGE1 and those receiving placebo, nitroglycerin, or tirofiban.

Main Outcome Measures

The primary endpoint of the study was the incidence of microcirculatory disturbances. Secondary outcomes included corrected thrombolysis in myocardial infarction (TIMI) frame count (cTFC), the percentage of patients with TIMI myocardial perfusion grade 3 (TMPG3), and the percentage of patients with myocardial blush grade 3 (MBG3) as efficacy indicators. Additionally, major adverse cardiovascular events (MACE) at 30 days and 180 days were assessed as safety indicators.

Results

There were 18 trials involving a total of 1458 participants. PGE1 significantly reduced the occurrence of microcirculation disorders compared with conventional medications and placebo [risk ratio 0.48, 95% confidence interval (CI) 0.36–0.63, I2 = 46%; cTFC (RR −4.74, 95% −6.85 to −2.63, I2 93%); percentage of patients with TMPG3 (RR 1.34, 95% CI 1.07–1.68, I2 70%) or MBG3 (RR 1.33, 95% CI 1.19–1.49, I2 0%); major adverse cardiovascular events (MACEs) in 30 days (RR 0.48, 95% CI 0.27–0.86, I2 0%); and MACEs in 180 days (RR 0.41, 95% CI 0.28–0.60, I2 0%)].

Conclusions

We found that PGE1 decreased the occurrence of micro-circulation disturbance in AMI and enhanced the outcome of PCI. Additional studies should be conducted to confirm these findings.
Appendix
Available only for authorised users
Literature
2.
go back to reference Duan T, Xiang D. Progress in the pathogenesis, diagnosis and treatment of coronary microcirculation disorders after acute myocardial infarction. Chin Circ J. 2019;34:722–5. Duan T, Xiang D. Progress in the pathogenesis, diagnosis and treatment of coronary microcirculation disorders after acute myocardial infarction. Chin Circ J. 2019;34:722–5.
3.
go back to reference Wang Q, Li Y. Treatment progress of slow flow or no reflow phenomenon in percutaneous coronary intervention. Med Recapitul. 2021;27:339–44. Wang Q, Li Y. Treatment progress of slow flow or no reflow phenomenon in percutaneous coronary intervention. Med Recapitul. 2021;27:339–44.
5.
go back to reference Liying GE, Jingguang HU, Xiaofei ZHU. Effect of intracoronary injection of alprostadil on the recovery of myocardial perfusion in patients with STEMI during PCI. J Clin Psychosomatic Dis. 2021;27(2):30–4. Liying GE, Jingguang HU, Xiaofei ZHU. Effect of intracoronary injection of alprostadil on the recovery of myocardial perfusion in patients with STEMI during PCI. J Clin Psychosomatic Dis. 2021;27(2):30–4.
6.
go back to reference Na S, Li B, Wei X, et al. Effect and mechanism of Shenfu injection pretreatment combined with intracoronary injection of alprostadil in preventing noreflow phenomenon after emergency percutaneous coronary intervention inpatients with acute coronary syndrome. Mod J Integr Tradition Chin Western Med. 2018;27(12):1272–7 (in Chinese). Na S, Li B, Wei X, et al. Effect and mechanism of Shenfu injection pretreatment combined with intracoronary injection of alprostadil in preventing noreflow phenomenon after emergency percutaneous coronary intervention inpatients with acute coronary syndrome. Mod J Integr Tradition Chin Western Med. 2018;27(12):1272–7 (in Chinese).
7.
go back to reference Ji J, He S, Chen S, Xu R, Liu X, Liao Q, Xu B, Zhang J, Zhang J. Effect of intracoronary prostaglandin E1 injection prior to percutaneous coronary intervention on myocardial microcirculation perfusion and clinical outcome in acute non-ST segment elevation myocardial infarction. Chin J Prim Med Pharm. 2018;25:419–23. Ji J, He S, Chen S, Xu R, Liu X, Liao Q, Xu B, Zhang J, Zhang J. Effect of intracoronary prostaglandin E1 injection prior to percutaneous coronary intervention on myocardial microcirculation perfusion and clinical outcome in acute non-ST segment elevation myocardial infarction. Chin J Prim Med Pharm. 2018;25:419–23.
8.
go back to reference Zhang G, An B, Zhang X, et al. Effect of intra-coronary injection of alprostadil on emergency percutaneous coronary intervention in ST segment elevation myocardial infarction. Chin J Gerontol. 2017;37(18):4540–1 (in Chinese). Zhang G, An B, Zhang X, et al. Effect of intra-coronary injection of alprostadil on emergency percutaneous coronary intervention in ST segment elevation myocardial infarction. Chin J Gerontol. 2017;37(18):4540–1 (in Chinese).
9.
go back to reference Wang J, Wang W, Lu Y. Effect of myocardial ischemic preconditioning combined with alprostadil on microcirculation and prognosis of patients with acute myocardial infarction after PCI. Chin J Integr Med Cardio-Cerebrovasc Dis. 2019;17(12):1887–90 (in Chinese). Wang J, Wang W, Lu Y. Effect of myocardial ischemic preconditioning combined with alprostadil on microcirculation and prognosis of patients with acute myocardial infarction after PCI. Chin J Integr Med Cardio-Cerebrovasc Dis. 2019;17(12):1887–90 (in Chinese).
10.
go back to reference Li H, Zhu J. Clinical study on the mechanism of percutaneous coronary intervention combined with alprostadil in the treatment of acute myocardial infarction. China Pharm. 2019;28(04):48–50 (in Chinese). Li H, Zhu J. Clinical study on the mechanism of percutaneous coronary intervention combined with alprostadil in the treatment of acute myocardial infarction. China Pharm. 2019;28(04):48–50 (in Chinese).
11.
go back to reference Tang K, Ren J, Zhang B. Effect of alprostadil on myocardial microcirculation disturbance of patients with ST-segment elevation acute myocardial infarction treated by percutaneous coronary intervention. Infect Inflamm Repair. 2018;19(03):164–9 (in Chinese). Tang K, Ren J, Zhang B. Effect of alprostadil on myocardial microcirculation disturbance of patients with ST-segment elevation acute myocardial infarction treated by percutaneous coronary intervention. Infect Inflamm Repair. 2018;19(03):164–9 (in Chinese).
12.
go back to reference Jiang X, Ye F, Shi L, et al. Alprostadil preconditioning had no effect on reflow during emergency percutaneous coronary intervention. Cardiovas Dis J Integr Tradition Chin Western Med Electron. 2016;4(6):53–5 (in Chinese). Jiang X, Ye F, Shi L, et al. Alprostadil preconditioning had no effect on reflow during emergency percutaneous coronary intervention. Cardiovas Dis J Integr Tradition Chin Western Med Electron. 2016;4(6):53–5 (in Chinese).
13.
go back to reference Guo S, Wang W, Luo Y, et al. The curative efficacy of alprostadil on the improvement of no-reflow after PCI operation in patients with acute myocardial infarction. J Pract Med. 2018;34(16):2761–5 (in Chinese). Guo S, Wang W, Luo Y, et al. The curative efficacy of alprostadil on the improvement of no-reflow after PCI operation in patients with acute myocardial infarction. J Pract Med. 2018;34(16):2761–5 (in Chinese).
14.
go back to reference Lin S, Zheng Y, Zheng C, et al. Effects of alprostadil on myocardial ischemia-reperfusion, serum inflammatory factors, oxidative stress and vascular endothelial function after PCI inpatients with ST-segment elevation acute myocardial infarction. Chin J Gerontol. 2020;40(24):5153–6 (in Chinese). Lin S, Zheng Y, Zheng C, et al. Effects of alprostadil on myocardial ischemia-reperfusion, serum inflammatory factors, oxidative stress and vascular endothelial function after PCI inpatients with ST-segment elevation acute myocardial infarction. Chin J Gerontol. 2020;40(24):5153–6 (in Chinese).
15.
go back to reference Sako H, Hadama T, Miyamoto S, et al. Effect of prostaglandin E1 on ischemia-reperfusion injury during abdominal aortic aneurysm surgery. Surg Today. 2006;36:140–6.CrossRefPubMed Sako H, Hadama T, Miyamoto S, et al. Effect of prostaglandin E1 on ischemia-reperfusion injury during abdominal aortic aneurysm surgery. Surg Today. 2006;36:140–6.CrossRefPubMed
16.
go back to reference Yang L. Effects of alprostadil injection on color Doppler echocardiography and electrocardiogram indexes after PCI in patients with acute myocardial infarction. Hebei Med J. 2020;42(11):1726–8 (in Chinese). Yang L. Effects of alprostadil injection on color Doppler echocardiography and electrocardiogram indexes after PCI in patients with acute myocardial infarction. Hebei Med J. 2020;42(11):1726–8 (in Chinese).
17.
go back to reference Weibin QIN. Study of gualou xiebai banxia decoction combined with alprostadil on myocardial microcirculation after PCI of coronary heart disease. Nanning: Guangxi University of Chinese Medicine; 2019. Weibin QIN. Study of gualou xiebai banxia decoction combined with alprostadil on myocardial microcirculation after PCI of coronary heart disease. Nanning: Guangxi University of Chinese Medicine; 2019.
18.
go back to reference Feng W, Xiong B. Effect of alprostadil on cardiac function of acute myocardial infarction patients treated by emergency percutaneous coronary intervention. Pract J Cardiac Cerebral Pneumal Vasc Dis. 2015;23(01):20–3 (in Chinese). Feng W, Xiong B. Effect of alprostadil on cardiac function of acute myocardial infarction patients treated by emergency percutaneous coronary intervention. Pract J Cardiac Cerebral Pneumal Vasc Dis. 2015;23(01):20–3 (in Chinese).
19.
go back to reference LU T, Tao G. Effect of alprostadil on myocardial perfusion inpatients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Chin J Arterioscler. 2019;27(04):337–43 (in Chinese). LU T, Tao G. Effect of alprostadil on myocardial perfusion inpatients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Chin J Arterioscler. 2019;27(04):337–43 (in Chinese).
20.
go back to reference Bao E, Li G, Pi L, et al. Effect of alprostadil combined with tirofiban on myocardial perfusion after emergency PCI. Pract Pharm Clin Remedies. 2019;22(04):382–5 (in Chinese). Bao E, Li G, Pi L, et al. Effect of alprostadil combined with tirofiban on myocardial perfusion after emergency PCI. Pract Pharm Clin Remedies. 2019;22(04):382–5 (in Chinese).
22.
go back to reference Zhang W, Dai J, Zheng X, Xu K, Yang X, Shen L, Wang X, Hao Z, Qiu X, Jiang L, Shi H, Shen L, He B. Myocardial protective effect of intracoronary administration of nicorandil and alprostadil via targeted perfusion microcatheter in patients undergoing elective percutaneous coronary intervention: a randomized controlled trial. Medicine (Baltimore). 2021;100(15):e25551. https://doi.org/10.1097/MD.0000000000025551.CrossRefPubMed Zhang W, Dai J, Zheng X, Xu K, Yang X, Shen L, Wang X, Hao Z, Qiu X, Jiang L, Shi H, Shen L, He B. Myocardial protective effect of intracoronary administration of nicorandil and alprostadil via targeted perfusion microcatheter in patients undergoing elective percutaneous coronary intervention: a randomized controlled trial. Medicine (Baltimore). 2021;100(15):e25551. https://​doi.​org/​10.​1097/​MD.​0000000000025551​.CrossRefPubMed
24.
go back to reference Ndrepepa G, Tiroch K, Fusaro M, et al. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention inpatients with acute myocardial infarction. J Am Coll Cardiol. 2010;55:2383–9.CrossRefPubMed Ndrepepa G, Tiroch K, Fusaro M, et al. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention inpatients with acute myocardial infarction. J Am Coll Cardiol. 2010;55:2383–9.CrossRefPubMed
25.
go back to reference Wu KC, Zerhouni EA, Judd RM, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation. 1998;97:765–72.CrossRefPubMed Wu KC, Zerhouni EA, Judd RM, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation. 1998;97:765–72.CrossRefPubMed
27.
go back to reference Nazir SA, Khan JN, Mahmoud IZ, et al. The REFLO-STEMI trial comparing intracoronary adenosine, sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction during primary percutaneous coronary intervention: study protocol for a randomized controlled trial. Trials. 2014;15:371.CrossRefPubMedPubMedCentral Nazir SA, Khan JN, Mahmoud IZ, et al. The REFLO-STEMI trial comparing intracoronary adenosine, sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction during primary percutaneous coronary intervention: study protocol for a randomized controlled trial. Trials. 2014;15:371.CrossRefPubMedPubMedCentral
30.
go back to reference Erer D, Ozer A, Demirtas H, et al. Effects of alprostadil and iloprost on renal, lung, and skeletal muscle injury following hindlimb ischemia-reperfusion injury in rats. Drug Des Dev Ther. 2016;10:2651–8.CrossRef Erer D, Ozer A, Demirtas H, et al. Effects of alprostadil and iloprost on renal, lung, and skeletal muscle injury following hindlimb ischemia-reperfusion injury in rats. Drug Des Dev Ther. 2016;10:2651–8.CrossRef
31.
go back to reference Gezginci-Oktayoglu S, Orhan N, Bolkent S. Prostaglandin-E1 has a protective effect on renal ischemia/reperfusion-induced oxidative stress and inflammation mediated gastric damage in rats. Int Immunopharmacol. 2016;36:142–50.CrossRefPubMed Gezginci-Oktayoglu S, Orhan N, Bolkent S. Prostaglandin-E1 has a protective effect on renal ischemia/reperfusion-induced oxidative stress and inflammation mediated gastric damage in rats. Int Immunopharmacol. 2016;36:142–50.CrossRefPubMed
32.
go back to reference Blogowski W, Dolegowska B, Pikula E, et al. The effect of PGE administration on the activity of oxidative system in erythrocytes and platelets during ischemia reperfusion injury and on postoperative renal function in patients undergoing open abdominal aortic aneurysm reconstruction. J Biol Regul Homeost Agents. 2012;26:429–38.PubMed Blogowski W, Dolegowska B, Pikula E, et al. The effect of PGE administration on the activity of oxidative system in erythrocytes and platelets during ischemia reperfusion injury and on postoperative renal function in patients undergoing open abdominal aortic aneurysm reconstruction. J Biol Regul Homeost Agents. 2012;26:429–38.PubMed
Metadata
Title
Efficacy and Safety of Alprostadil in Microcirculatory Disturbances During Emergency PCI: A Meta-Analysis of Randomized Controlled Trials
Authors
Yue Chen
Mengdi Wang
Yali Yang
Min Zeng
Publication date
08-06-2024
Publisher
Springer International Publishing
Published in
American Journal of Cardiovascular Drugs
Print ISSN: 1175-3277
Electronic ISSN: 1179-187X
DOI
https://doi.org/10.1007/s40256-024-00655-3